Stock Screener > Stock Ideas > Biotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Forecast Score | Market Cap | Price | Price Target | Upside/Downside | Consensus | Analysts | Fore. Revenue Growth | Fore. Earnings Growth | Forecast ROE | Forecast ROA |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VCEL | Vericel Corp | 89 | $2.44B | $53.10 | $42.00 | -20.90% | Strong Buy | 6 | 25.99% | 115.91% | 88.17% | 58.46% |
| HALO | Halozyme Therapeutics Inc | 89 | $6.45B | $47.69 | $44.50 | -6.69% | Strong Buy | 2 | 42.22% | 54.58% | 336.51% | 87.65% |
| EXEL | Exelixis Inc | 89 | $7.20B | $23.22 | $30.80 | 32.64% | Buy | 5 | 26.36% | 63.36% | 39.02% | 34.30% |
| INCY | Incyte Corp | 78 | $18.10B | $82.31 | $90.25 | 9.65% | Hold | 5 | 14.81% | 33.44% | 62.62% | 46.65% |
| BDSI | Biodelivery Sciences International Inc | 78 | $321.03M | $3.18 | $5.50 | 73.23% | Buy | 1 | 17.05% | 43.85% | 94.35% | 42.57% |
| BNTX | BioNTech SE | 67 | $38.10B | $168.00 | $113.00 | -32.74% | Hold | 5 | 48.62% | 224.74% | -64.39% | -38.10% |
| CARA | Cara Therapeutics Inc | 67 | $619.91M | $12.44 | $33.00 | 165.27% | Strong Buy | 2 | 9.51% | 23.74% | 33.52% | 30.78% |
| VNDA | Vanda Pharmaceuticals Inc | 67 | $957.65M | $17.51 | $14.00 | -20.05% | Hold | 1 | 12.52% | 50.76% | 26.18% | 22.25% |
| ALXN | Alexion Pharmaceuticals Inc | 67 | $37.32B | $169.86 | $175.40 | 3.26% | Hold | 6 | 6.95% | 63.43% | 21.78% | 14.50% |
| RPRX | Royalty Pharma plc | 56 | $15.93B | $41.05 | $53.00 | 29.11% | Buy | 6 | 4.03% | 37.10% | 31.09% | 9.35% |
| NBIX | Neurocrine Biosciences Inc | 56 | $8.40B | $89.43 | $124.50 | 39.22% | Buy | 11 | 21.02% | 11.69% | 56.81% | 37.09% |
| ABCM | Abcam plc | 56 | $4.67B | $20.75 | $22.00 | 6.02% | Hold | 3 | 15.22% | 75.95% | 16.28% | 10.08% |
| CORT | Corcept Therapeutics Inc | 56 | $2.52B | $21.71 | $23.33 | 7.48% | Buy | 3 | 15.76% | 19.70% | 44.17% | 40.44% |
| UTHR | UNITED THERAPEUTICS Corp | 44 | $8.56B | $192.07 | $219.20 | 14.13% | Buy | 5 | 10.21% | 19.86% | 23.25% | 17.26% |
| REGN | Regeneron Pharmaceuticals Inc | 33 | $53.42B | $498.68 | $632.80 | 26.90% | Buy | 15 | 8.06% | 3.67% | 39.49% | 26.61% |
| VRTX | Vertex Pharmaceuticals Inc | 33 | $55.41B | $213.16 | $277.55 | 30.21% | Buy | 11 | 8.96% | 3.84% | 38.15% | 28.28% |
| SIGA | Siga Technologies Inc | 33 | $567.34M | $7.33 | N/A | N/A | N/A | N/A | -4.63% | 7.04% | 48.30% | 41.84% |
| NVO | Novo Nordisk A S | 33 | $174.37B | $74.20 | N/A | N/A | Strong Buy | 1 | 7.89% | 9.04% | 104.15% | 43.09% |
| TECH | BIO-TECHNE Corp | 22 | $15.87B | $410.98 | $386.43 | -5.97% | Strong Buy | 8 | 11.60% | 13.36% | 17.28% | 12.72% |
| JAZZ | Jazz Pharmaceuticals plc | 11 | $9.74B | $172.84 | $192.60 | 11.43% | Buy | 10 | 5.16% | 13.83% | N/A | N/A |
©2021 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.